Enzon Pharmaceuticals Inc (ENZN) financial statements (2020 and earlier)

Company profile

Business Address 20 COMMERCE DRIVE, SUITE 135
CRANFORD, NJ 07016
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1077812357
Cash and cash equivalents1077812357
Receivables114    
Assets held-for-sale0
Deferred tax assets    7794
Other current assets0000001
Other undisclosed current assets 7(4)   (94)
Total current assets:111588121127
Noncurrent Assets
Nontrade receivables112   
Assets held-for-sale, long lived0
Deferred tax assets, net  311  
Other undisclosed noncurrent assets      (0)
Total noncurrent assets:112311  
Other undisclosed assets     (77) 
TOTAL ASSETS:1216101123357
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6101051
Accounts payable0001000
Accrued liabilities0000001
Employee-related liabilities     0 
Interest and dividends payable5    4 
Other undisclosed current liabilities    5(0) 
Total current liabilities:6101551
Noncurrent Liabilities
Liabilities, other than long-term debt     0 
Accounts payable and accrued liabilities     0 
Other undisclosed noncurrent liabilities      1
Total noncurrent liabilities:     01
Total liabilities:6101552
Stockholders' equity
Stockholders' equity attributable to parent61591018305
Common stock0000000
Additional paid in capital7684849097130135
Accumulated deficit(70)(69)(75)(80)(79)(101)(130)
Total stockholders' equity:61591018305
TOTAL LIABILITIES AND EQUITY:1216101123357

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net88173134
Gross profit:7788173134
Operating expenses(1)(1)(1)(2)(7)(2)(16)
Operating income:6677112918
Nonoperating income     02
Investment income, nonoperating      1
Other nonoperating income     02
Interest and debt expense      (2)
Income from continuing operations before income taxes:6677112918
Income tax expense (benefit)(0)(0)(2)(8)11(0)0
Net income (loss) available to common stockholders, diluted:665(1)222918

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):665(1)222918
Comprehensive income (loss):665(1)222918
Other undisclosed comprehensive loss, net of tax, attributable to parent      (0)
Comprehensive income (loss), net of tax, attributable to parent:665(1)222918

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: